Division of Pediatric Neurology, Department of Pediatrics, Duke University Medical Center, T0913 Children's Health Center, DUMC Box 3936, 2301 Erwin Rd, Durham, NC, 27710, USA.
Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 9 and Hunnewell 2, Boston, MA, 02115, USA; Facultad de Medicina, Universidad Austral de Chile, Valdiva, Chile.
Seizure. 2017 Oct;51:74-76. doi: 10.1016/j.seizure.2017.07.018. Epub 2017 Aug 5.
To report novel clinical manifestations of KCNA2 mutation related epileptic encephalopathy.
Blood samples were sent for whole exome and Sanger sequencing. Seizure types were characterized by clinical criteria and EEG recording.
KCNA2 mutations have been reported in 10 cases who presented with focal, absence, generalized tonic-clonic or myoclonic astatic seizures. Here we describe 3 patients with previously unreported, more severe manifestations. Patient 1 is a 5 year-old male with a c.1214 C > T (p.Pro405Leu) mutation, previously reported to be disease causing. He presented at 1year of age with focal seizures and subsequently developed electrical status epilepticus of sleep at age 3. The latter finding to our knowledge has never been reported in patients with KCNA2 mutations. Patient 2 is a 7 year-old female with a novel c.1195 G > A (p.Val399Met) mutation not previously described. She presented with intermittent then continuous polymyoclonus and myoclonic-astatic and generalized tonic clonic seizures. Continuous polymyoclonus is another new manifestation in patients with KCNA2 mutations. Patient 3 is a 23 year-old male with a c.889C > T (p.Arg297Trp) mutation not previously described. He presented at 4 years of age with generalized tonic clonic seizures and later developed recurrent refractory status epilepticus episodes at ages 19, 22 and 23 years, the latter being a novel manifestation in patients with KCNA2 mutations.
We identified 3 patients with KCNA2 mutations with novel characteristics, including electrical status epilepticus of sleep, continuous polymyoclonus and status epilepticus. These results expand KCNA2 mutation epileptic manifestations to include more severe, previously unreported phenotypes.
报告 KCNA2 突变相关癫痫性脑病的新的临床表型。
送检血样进行全外显子组和 Sanger 测序。根据临床标准和脑电图记录对癫痫发作类型进行特征描述。
KCNA2 突变已在 10 例表现为局灶性、失神性、全面强直阵挛性或肌阵挛性癫痫发作的患者中报道过。在这里,我们描述了 3 例具有先前未报道的更严重表现的患者。患者 1 为 5 岁男性,携带 c.1214 C > T(p.Pro405Leu)突变,该突变此前被报道为致病性突变。他在 1 岁时出现局灶性癫痫发作,随后在 3 岁时出现睡眠中电持续状态癫痫发作。据我们所知,后者的发现从未在 KCNA2 突变患者中报道过。患者 2 为 7 岁女性,携带一种新的 c.1195 G > A(p.Val399Met)突变,该突变此前未被描述过。她表现为间歇性继而持续性多灶性肌阵挛和肌阵挛-猝倒性及全面强直阵挛性癫痫发作。持续性多灶性肌阵挛是 KCNA2 突变患者的另一种新表现。患者 3 为 23 岁男性,携带一种新的 c.889C > T(p.Arg297Trp)突变,该突变此前未被描述过。他在 4 岁时出现全面强直阵挛性癫痫发作,随后在 19、22 和 23 岁时出现反复难治性癫痫持续状态发作,这是 KCNA2 突变患者的一种新表现。
我们鉴定了 3 例具有新特征的 KCNA2 突变患者,包括睡眠中电持续状态癫痫发作、持续性多灶性肌阵挛和癫痫持续状态。这些结果将 KCNA2 突变癫痫发作表现扩展为包括更严重的、以前未报道的表型。